Endo International PLC ENDP
We take great care to ensure that the data presented and summarized in this overview for Endo International plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ENDP
Top Purchases
Top Sells
About ENDP
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Insider Transactions at ENDP
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 15
2022
|
James Patrick Tursi Executive VP, Global R&D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
280,373
-100.0%
|
-
|
Mar 30
2022
|
Blaise Coleman President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,137
-2.35%
|
$20,274
$2.52 P/Share
|
Mar 30
2022
|
Blaise Coleman President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,910
+7.67%
|
-
|
Mar 30
2022
|
Blaise Coleman President, CEO |
SELL
Exercise of conversion of derivative security
|
Direct |
89,663
-6.26%
|
-
|
Mar 30
2022
|
Mark T. Bradley EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,057
-2.92%
|
$6,114
$2.52 P/Share
|
Mar 30
2022
|
Mark T. Bradley EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,735
+9.31%
|
-
|
Mar 30
2022
|
Mark T. Bradley EVP, Chief Financial Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
26,805
-10.01%
|
-
|
Mar 30
2022
|
Matthew Joseph Maletta EVP, CLO & Company Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
10,179
-2.82%
|
$20,358
$2.52 P/Share
|
Mar 30
2022
|
Matthew Joseph Maletta EVP, CLO & Company Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
34,414
+8.7%
|
-
|
Mar 30
2022
|
Matthew Joseph Maletta EVP, CLO & Company Secretary |
SELL
Exercise of conversion of derivative security
|
Direct |
85,927
-17.07%
|
-
|
Mar 30
2022
|
Patrick A Barry EVP & Pres,Global Comm Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
4,975
-2.85%
|
$9,950
$2.52 P/Share
|
Mar 30
2022
|
Patrick A Barry EVP & Pres,Global Comm Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
16,957
+8.85%
|
-
|
Mar 30
2022
|
Patrick A Barry EVP & Pres,Global Comm Ops |
SELL
Exercise of conversion of derivative security
|
Direct |
42,341
-12.86%
|
-
|
Mar 29
2022
|
Blaise Coleman President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,437
-2.08%
|
$16,874
$2.52 P/Share
|
Mar 29
2022
|
Mark T. Bradley EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,544
-2.64%
|
$5,088
$2.52 P/Share
|
Mar 29
2022
|
Matthew Joseph Maletta EVP, CLO & Company Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
8,472
-2.53%
|
$16,944
$2.52 P/Share
|
Mar 29
2022
|
Frank B. Raciti VP, Controller and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
965
-9.86%
|
$1,930
$2.52 P/Share
|
Mar 29
2022
|
Patrick A Barry EVP & Pres,Global Comm Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
4,141
-2.56%
|
$8,282
$2.52 P/Share
|
Mar 05
2022
|
Matthew Joseph Maletta EVP, CLO & Company Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
9,120
-2.89%
|
$18,240
$2.34 P/Share
|
Mar 05
2022
|
Blaise Coleman President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,886
-7.84%
|
$63,772
$2.34 P/Share
|